Figure 6.
Effect of TF inhibition in mouse xenograft and allograft models of APL. For the xenograft model, we intravenously injected 100 μg of an inhibitory mouse anti-human TF antibody (HTF-1) or mouse control IgG per mouse on day 21. On day 28, blood was collected, and plasma was prepared or tail bleeding was performed. (A) TAT, (B) platelet count, (C) MPV, (D) sP-selectin, and (E) tail bleeding time (n = 5-7 per group). For the allograft model, we injected 20 mg/kg of an inhibitory rat anti-mouse TF antibody (1H1) or rat control IgG into the APL intraperitoneally on day 17. On day 24, blood was collected and plasma was prepared. (F) TAT, (G) platelet count, (H) MPV, and (I) sP-selectin are shown (n = 8 per group). Data are shown as median ± interquartile range (A,G-I) or mean ± SD (B-F), depending on normality. The Mann-Whitney U test (A,G-I), unpaired 2-tailed Student t test (B-D,F), or Welch t test (E) was used. ∗P < .05; ∗∗P < .01; ∗∗∗P < .001.

Effect of TF inhibition in mouse xenograft and allograft models of APL. For the xenograft model, we intravenously injected 100 μg of an inhibitory mouse anti-human TF antibody (HTF-1) or mouse control IgG per mouse on day 21. On day 28, blood was collected, and plasma was prepared or tail bleeding was performed. (A) TAT, (B) platelet count, (C) MPV, (D) sP-selectin, and (E) tail bleeding time (n = 5-7 per group). For the allograft model, we injected 20 mg/kg of an inhibitory rat anti-mouse TF antibody (1H1) or rat control IgG into the APL intraperitoneally on day 17. On day 24, blood was collected and plasma was prepared. (F) TAT, (G) platelet count, (H) MPV, and (I) sP-selectin are shown (n = 8 per group). Data are shown as median ± interquartile range (A,G-I) or mean ± SD (B-F), depending on normality. The Mann-Whitney U test (A,G-I), unpaired 2-tailed Student t test (B-D,F), or Welch t test (E) was used. ∗P < .05; ∗∗P < .01; ∗∗∗P < .001.

Close Modal

or Create an Account

Close Modal
Close Modal